Nordea Trims Biogen Stake by 89%

Investment firm reduces holdings in biotech company during Q4 2025

Mar. 28, 2026 at 9:48am

Got story updates? Submit your updates here. ›

Nordea Investment Management AB significantly reduced its stake in Biogen Inc. (NASDAQ:BIIB) by 89.4% during the fourth quarter of 2025, according to a recent SEC filing. The fund now owns just 14,022 shares of the biotechnology company's stock, down from 132,583 shares previously.

Why it matters

This large reduction in Nordea's Biogen holdings suggests the investment firm has grown more cautious on the biotech company's prospects, potentially due to factors like competition, pipeline challenges, or valuation concerns. Biogen's stock price has been volatile in recent years, making it an important holding to track for investors.

The details

Nordea Investment Management AB sold 118,561 shares of Biogen during Q4 2025, reducing its total position to just 14,022 shares worth $2.458 million. The firm previously held 132,583 shares of the biotechnology company.

  • Nordea filed its Q4 2025 holdings with the SEC on March 28, 2026.

The players

Nordea Investment Management AB

A major European asset management firm that has been an investor in Biogen.

Biogen Inc.

A multinational biotechnology company focused on developing therapies for neurological and neurodegenerative diseases.

Got photos? Submit your photos here. ›

The takeaway

Nordea's significant reduction in its Biogen stake suggests the investment firm has grown more cautious on the biotech company's outlook, potentially due to factors like increased competition, pipeline challenges, or valuation concerns. This move is worth watching as an indicator of broader investor sentiment around Biogen.